Tepmetko (Tepotinib) 225mg*60 | Merck KGaA Germany Originator | GLT

Generic Information: Tepmetko (Tepotinib) 225mg — Germany

Tepmetko is the originator brand of tepotinib, developed by Merck KGaA of Darmstadt, Germany. Tepotinib is notable as the first oral MET inhibitor to be approved anywhere in the world: Japan granted it the global first approval, and it has since been authorised in the United States, Europe and China for MET exon 14 skipping-mutated non-small cell lung cancer. This listing is the German-sourced presentation — 225 mg film-coated tablets in a 60-tablet pack, matching the standard 450 mg once-daily regimen of two tablets per day.

As the reference product, Tepmetko carries the most complete clinical dataset of any tepotinib product, anchored by the VISION study. Merck KGaA (not to be confused with the separate US-based Merck & Co.) manufactures and distributes Tepmetko across its European and Asian markets, so buyers should confirm the market of origin when sourcing, as labelling and import documentation differ by region.

What Is Tepmetko Used For?

Tepmetko treats advanced non-small cell lung cancer whose tumour harbours a MET exon 14 skipping alteration. The mutation is detected by next-generation sequencing or another validated diagnostic and is present in roughly a small single-digit percentage of NSCLC cases. Tepmetko is indicated for adults with this mutation, including treatment-naive and previously treated patients, providing an oral targeted option where conventional chemotherapy or immunotherapy may be less suited.

How Does Tepmetko Work?

Tepotinib is a selective MET tyrosine kinase inhibitor. In MET exon 14-mutated NSCLC, the altered MET receptor escapes normal degradation and stays active, continuously signalling for cell proliferation. Tepmetko binds and blocks this overactive MET kinase, interrupting the growth signal. Its oral once-daily dosing and brain-penetrant properties are among the reasons it is a preferred agent for this molecular subtype.

Indications

• Metastatic non-small cell lung cancer with MET exon 14 skipping mutation, confirmed by a validated test.
• Adult patients, in the first-line or later setting, where the mutation is present.

Dosage and Administration

The recommended dose of Tepmetko is 450 mg once daily, given as two 225 mg tablets taken together, with or without food. The tablets are swallowed whole. A 60-tablet pack supplies 30 days of treatment. Dose modification or interruption may be needed for oedema, liver enzyme elevations or other adverse reactions, and regular monitoring of liver function is recommended throughout therapy.

Side Effects

Common adverse reactions include peripheral oedema, nausea, diarrhoea, fatigue and decreased appetite. Elevations in liver enzymes (ALT/AST) are a recognised, monitorable effect. Rare but serious risks include interstitial lung disease/pneumonitis and QT prolongation; patients should report new cough, breathlessness, palpitations or marked swelling to their clinician.

Storage

Store Tepmetko at or below 30°C in the original package, away from moisture and out of the sight and reach of children. Use before the printed expiry date.

Why Choose the GLT?

GLT can source the originator Tepmetko and its regional presentations for buyers who specifically require the Merck KGaA brand, together with documentation for import and compliance. While the German and US list prices of Tepmetko are high, GLT helps institutions and patients identify the most cost-effective compliant supply route and provides clear, responsive ordering support from inquiry through delivery.

How to Order Tepmetko from GLT

Contact GLT on WhatsApp at +86 15234153837 or email [email protected] to inquire about Tepmetko 225 mg (60 tablets). Specify your required market presentation (Germany or China), quantity and destination. We confirm pricing, batch origin and shipping documentation before dispatch.

FAQ

Is Tepmetko the original tepotinib? Yes, Tepmetko is the originator brand developed by Merck KGaA (Darmstadt, Germany); all other tepotinib products are generics of it.

What is the difference between German and Chinese Tepmetko? The active ingredient and dose are identical; the difference is market packaging, labelling and import documentation.

Where was tepotinib first approved? Tepotinib received its first global approval in Japan as an oral MET inhibitor for MET exon 14-mutated NSCLC.